| Long name: |
GLP-2 Primary Polyclonal Antibody |
| Also known as: |
GLP-2 PAb |
| Category: |
Primary Antibodies |
| Conjugation: |
Unconjugated |
| Target Antigen: |
GLP-2 |
| Specificity: |
This is a highly specific antibody against GLP-2 |
| Modification(s): |
None |
| Modification site(s): |
Unmodified antibody |
| Clonality: |
Polyclonal antibody |
| Clone number: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Immunogen range: |
146-178/180 |
| Subcellular location: |
Secreted |
| Source: |
This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human GLP-2 |
| Gene ID number: |
2641 |
| Swiss Prot: |
P01275 |
| Tested Applications: |
IF(IHC-P), IHC-P, WB |
| Recommended dilutions: |
IF(IHC-P)(1:50-200), IHC-P(1:100-500), WB(1:100-1000) |
| Cross reactivity: |
Mouse, Rat, Human |
| Cross reactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Background of the target antigen: |
A counterregulatory hormone of insulin, CRH, GLP-1 is a potent stimulator of glucose-dependent insulin release, GLP-2 stimulates intestinal growth and up-regulates villus height in the small intestine, Glicentin may modulate gastric acid secretion and the gastro-pyloro-duodenal activity, Have growth-promoting activities on intestinal epithelium, Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation, Inhibits beta cell apoptosis, Inhibits gastric emptying in humans, May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, May play an important role in intestinal mucosal growth in the early period of life, Oxyntomodulin significantly reduces food intake, Play important roles on gastric motility and the suppression of plasma glucagon levels, Plays a key role in nutrient homeostasis, Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes, Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis, Stimulates intestinal glucose transport and decreases mucosal permeability, Suppression of gastric emptying may lead to increased gastric distension, TSH, The gastrointestinal tract, and vasopressin secretion, as well as increasing nutrient disposal, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis, enhancing nutrient assimilation through enhanced gastrointestinal function, from the stomach to the colon is the principal target for GLP-2 action, independent of the actions of insulin, oxytocin, raises plasma glucose levels in response to insulin-induced hypoglycemia, which may contribute to satiety by causing a sensation of fullness, Glucagon plays a key role in glucose metabolism and homeostasis |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA |
| Synonym names: |
GCG, GLP2, GRPP, Glucagon, GLP1 |
| Properties: |
C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
GLP-2 |
| Short name: |
GLP-2 Antibody |
| Technique: |
antibodies against human proteins, antibodies for, Antibody |
| Alternative name: |
GLP-2 (Antibody to) |
| Alternative technique: |
antibodies |